Overview
Aptus Endosystems is a privately held, well-funded, emerging medical device company that is engaged in the development of next generation minimally invasive endograft devices, delivery systems and fixation technology for the treatment of Abdominal Aortic Aneurysms - the 13th leading cause of death in the United States and the 10th leading cause of death in men over the age of 55. The Company is addressing a potential worldwide market opportunity in excess of $1B
Background
Aptus Endosystems was co-founded in 2002 by Alan Kaganov, company Chairman, and a partner at the venture capital firm of US Venture Partners, and Lee Bolduc, the company's Vice President of Engineering and Chief Technical Officer; with the mission to develop products that enable safe and durable endovascular repair for a broader base of patients that present with abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA).
In 2002, the company closed a Series A1 round of venture funding from U.S. Venture Partners and a Series A2 round co-led by U.S. Venture Partners and new investor Pequot Ventures. The company subsequently completed the initial design and a series of preclinical tests on its first generation AAA endograft system, along with its enabling, proprietary endostapling technology. Additionally, the company successfully completed "first-in man" implants.
In the first quarter of 2006 Aptus Endosystems closed a Series B round of venture financing led by new investor Prism VentureWorks, with a co-investment from Baird Venture Partners and with full participation from the existing investor group.
Today, Aptus Endosystems is located in a 12,000 sq. ft. facility in Sunnyvale, CA and has completed a Phase I (STAPLE-1) Clinical Trial in the US. A Phase II (STAPLE-2) Clinical Trial has been initiated in the US as part of its commercialization efforts for the Aptus™ Endovascular AAA Repair System, and as well pursuing next generation designs and technologies applicable to the TAA market.